- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 1,126 of 2,219.
| EudraCT Number: 2006-005262-39 | Sponsor Protocol Number: 2006-2209 | Start Date*: 2007-05-30 |
| Sponsor Name:Charité-Universitätsmedizin Berlin | ||
| Full Title: Flupirtin as Oral Treatment in MS | ||
| Medical condition: Relapsing-remitting multiple sclerosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-005451-23 | Sponsor Protocol Number: T-01 | Start Date*: 2009-05-27 |
| Sponsor Name:Charité - Universitätsmedizin Berlin, CharitéCentrum 3 für Zahn-, Mund- und Kieferheilkunde | ||
| Full Title: Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin | ||
| Medical condition: Xerostomia and substantial relief of the symptoms by saliva substitutes | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-017739-17 | Sponsor Protocol Number: ISI-2009LGE | Start Date*: 2010-02-12 | ||||||||||||||||||||||||||
| Sponsor Name:Charité | ||||||||||||||||||||||||||||
| Full Title: Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem | ||||||||||||||||||||||||||||
| Medical condition: Patients with a history of chronic myocardial infarction | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2012-004111-32 | Sponsor Protocol Number: OTRAPAC | Start Date*: 2013-03-01 | |||||||||||
| Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
| Full Title: Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application... | |||||||||||||
| Medical condition: Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-017458-11 | Sponsor Protocol Number: DEP-HOM | Start Date*: 2010-06-10 |
| Sponsor Name:Institute for Social Medicine, Epidemiology, and Health Economics, Charité Berlin | ||
| Full Title: Homeopathy for Depression: a randomized, four-armed, partial double-blind study. | ||
| Medical condition: F32.1 Moderate Depressive Episode | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-007237-47 | Sponsor Protocol Number: PHYDELIO | Start Date*: 2009-01-15 |
| Sponsor Name:Charité - Universitätsmedizin Berlin | ||
| Full Title: Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction Perioperative Gabe von Physostigmin bei Leberteilresktion zur Prop... | ||
| Medical condition: The drug physostigmine will be investigated in patients (men and women)undergoing a liver resection. The study medication will be administered by intravenous infusion continuously (24 hours) to pre... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-003746-41 | Sponsor Protocol Number: CIGE025EDE14T | Start Date*: 2012-01-12 | |||||||||||
| Sponsor Name:Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin | |||||||||||||
| Full Title: A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticari... | |||||||||||||
| Medical condition: Cold contact urticaria | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002795-42 | Sponsor Protocol Number: C04-002 | Start Date*: 2005-02-16 | |||||||||||
| Sponsor Name:ALEXION PHARMACEUTICALS INCORPORATED | |||||||||||||
| Full Title: Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study | |||||||||||||
| Medical condition: paroxysmal nocturnal hemoglobinuria | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) IE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001319-23 | Sponsor Protocol Number: 3142A1-202-WW | Start Date*: 2005-07-22 |
| Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development | ||
| Full Title: A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate T... | ||
| Medical condition: Rheumatoid arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) ES (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001037-15 | Sponsor Protocol Number: NK-104-304 | Start Date*: 2006-05-17 | |||||||||||
| Sponsor Name:Kowa Research Europe Ltd. | |||||||||||||
| Full Title: STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASE | |||||||||||||
| Medical condition: Hypercholesterolemia or Combined Dyslipidemia and 2 or more risk factors for coronary heart disease (CHD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) GB (Completed) DK (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-002949-40 | Sponsor Protocol Number: SAM104926 | Start Date*: 2005-11-07 |
| Sponsor Name:GlaxoSmithKline Centre of Excellence | ||
| Full Title: A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticaso... | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: LT (Completed) NO (Completed) ES (Completed) SE (Completed) LV (Completed) BE (Completed) IT (Completed) DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-001905-93 | Sponsor Protocol Number: EGF102580 | Start Date*: 2005-07-11 |
| Sponsor Name:GlaxoSmithKline R&D Ltd | ||
| Full Title: A Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer | ||
| Medical condition: Newly diagnosed infammatory breast cancer (IBC) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000444-84 | Sponsor Protocol Number: EMR62225-030 | Start Date*: 2005-06-22 |
| Sponsor Name:Merck KGaA | ||
| Full Title: An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from... | ||
| Medical condition: Treatment-Associated Dyskinesia in Parkinson's Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) FI (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-001224-21 | Sponsor Protocol Number: MV18220 | Start Date*: 2005-01-14 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral (ARV) to enfuvirtide (ENF) and to assess resolution or improvement of ARV t... | |||||||||||||
| Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-004905-11 | Sponsor Protocol Number: D5890C00002 | Start Date*: 2005-06-21 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus... | |||||||||||||
| Medical condition: This is a Phase IIIB study to be performed in adult and adolescent asthmatic patients. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-004386-15 | Sponsor Protocol Number: MBG308 | Start Date*: Information not available in EudraCT |
| Sponsor Name:GE Healthcare Limited and its affiliates | ||
| Full Title: An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma | ||
| Medical condition: Phaeochromocytoma and Neuroblastoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-002437-39 | Sponsor Protocol Number: SPI-103 | Start Date*: 2004-12-21 |
| Sponsor Name:Daiichi Asubio Pharmaceuticals Inc. | ||
| Full Title: A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuo... | ||
| Medical condition: Treatment of acute stroke. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) ES (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000720-16 | Sponsor Protocol Number: 3082B2-310-WW | Start Date*: 2005-06-22 |
| Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals, Inc. | ||
| Full Title: A Randomised, Two-way, Blinded, Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) with a Full-Length Recombinant Factor VIII... | ||
| Medical condition: For all patients participating in the trial:Male subjects with severe or moderately severe hemophilia A (FVIII:C ≤ 2%) previously treated with ≥ 150 exposure days to any Factor VIII product.For pat... | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |
| Trial protocol: HU (Completed) ES (Completed) DE (Completed) SE (Completed) FI (Completed) BE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-001242-17 | Sponsor Protocol Number: BY9010/M1-207 | Start Date*: 2005-07-18 | |||||||||||
| Sponsor Name:ALTANA Pharma AG | |||||||||||||
| Full Title: Efficacy and Safety – Study by ALTANA on Ciclesonide in Pre-school Asthma Patients | |||||||||||||
| Medical condition: asthma bronchiale | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) ES (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-002969-37 | Sponsor Protocol Number: RA3103730 | Start Date*: 2005-10-14 |
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
| Full Title: A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship. | ||
| Medical condition: Rheumatoid Arthritis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) ES (Completed) DE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.